ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Von Eschenbach says oncology is undergoing a “revolutionary evolution.”

May 20, 2005

Flood Mistrial

February 9, 1979

NCI Human Tissue Network Resources Available For Research

January 24, 1997

Anidulafungin Safe And Well-Tolerated In Pediatric Patients With Neutropenia

November 26, 2004

Republican Congress To Shift Priorities, But Cancer May Get New Opportunities

November 18, 1994

“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s

September 20, 1991